FCD105
Total Payments
$1.5M
Transactions
263
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.5M | 263 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 263 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FX2016-40 | VYNE Pharmaceuticals Inc. | $1.5M | 0 |
Top Doctors Receiving Payments for FCD105
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $1.5M | 263 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 0
- Transactions 263
About FCD105
FCD105 is a drug associated with $1.5M in payments to 0 healthcare providers, recorded across 263 transactions in the CMS Open Payments database. The primary manufacturer is VYNE Pharmaceuticals Inc..
Payment data is available from 2020 to 2020. In 2020, $1.5M was paid across 263 transactions to 0 doctors.
The most common payment nature for FCD105 is "Unspecified" ($1.5M, 100.0% of total).
FCD105 is associated with 1 research study, including "FX2016-40" ($1.5M).